Raludotatug deruxtecan (R-DXd) earned FDA breakthrough designation for CDH6-expressing platinum-resistant ovarian cancers after bevacizumab (Avastin; Genentech) treatment.
Jax DiEugenio
Advertisement
Articles by Jax DiEugenio
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Climate Change Will Affect Pulmonary Health Across Intensive Care
2
The Growing ADC Landscape in TNBC Brings Questions, Opportunities: Rebecca Dent, MD, MSc
3
Brensocatib Reduced Symptom Burden, Neutrophil Serine Proteases Activity in Bronchiectasis
4
Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal
5
